FMP
Harmony Biosciences Holdings, Inc.
HRMY
NASDAQ
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
32.72 USD
0 (0%)
HRMY Financial Statements
Year
2024
2023
2022
2021
CF from Operating Activities
219.82M
219.39M
144.47M
98.56M
Net Income
145.49M
128.85M
181.47M
34.6M
Depreciation & Amortization
24.11M
24.36M
23.39M
18.84M
Deferred Income Taxes
-29.3M
-13.42M
-85.94M
26.15M
Stock Based Compensation
42.6M
31.7M
26.17M
15.66M
Change in Working Capital
0
35.03M
-4.11M
631k
Accounts Receivable
-8.89M
-19.4M
-19.9M
-12.67M
Inventory
-1.83M
-1.07M
135k
-609k
Accounts Payable
0
8.95M
2.79M
-1.55M
Other Working Capital
0
46.55M
12.87M
15.46M
Other Non-Cash Items
36.91M
12.85M
3.49M
2.68M
CF from Investing Activities
-67.48M
-46.44M
-141.83M
-100.3M
Investments in Property, Plant & Equipment
-1.15M
-312k
-40.17M
-100.3M
Net Acquisitions
-33.07M
-36.97M
141.83M
-100M
Investment Purchases
-105.29M
-127.47M
-110.73M
0
Sales/Maturities of Investments
98.53M
118.31M
9.07M
0
Other Investing Activites
-26.5M
0
-141.83M
100M
CF from Financing Activities
-11M
-105.55M
6.84M
7.42M
Debt Repayment
-15M
-4.75M
-2M
-222.5M
Common Stock Issued
0
0
8.84M
30M
Common Stock Repurchased
0
-100M
0
0
Dividends Paid
0
0
0
0
Other Financing Activites
4M
-3.79M
8.84M
-22.08M
Free Cash Flow
218.67M
219.07M
104.29M
-1.74M
Operating Cash Flow
219.82M
219.39M
144.47M
98.56M
Capital Expenditures
-1.15M
-312k
-40.17M
-100.3M
Cash at Beginning of Period
311.93M
244.53M
235.06M
229.38M
Cash at End of Period
453.27M
311.93M
244.53M
235.06M
Net Change In Cash
141.34M
67.4M
9.47M
5.68M
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-143.28M
-272.13M
-453.6M
-488.19M
Net Income
145.49M
128.85M
181.47M
34.6M
Stock Repurchases
0
-100M
0
0
Dividend Paid
0
0
0
0
Retained Earnings
2.22M
-143.28M
-272.13M
-453.6M
Other Distributions
145.49M
28.85M
181.47M
34.6M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
1.26M
371k
573k
820k
Annual Depreciation
24.11M
24.36M
23.39M
18.84M
Capital Expenditure
-1.15M
-312k
-40.17M
-100.3M
Net PPE
-21.7M
-23.68M
17.36M
82.28M
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
